Acrongenomics Inc. Announces $1,000,000 Private Placement to Fund Ongoing Operations.

ATHENS, Greece -- Acrongenomics Inc. (OTCBB:AGNM) announces today that it is commencing a private placement financing for 400,000 shares at $2.50 per share. A finders fee of ten percent in stock will be paid upon closing of the private placement. Proceeds from this financing will be used to fund the company's ongoing validation studies for its first product, the NeoEpCAM Detection Kit(TM), for new product research and development and for general corporate purposes.

Dr. Leftheris Georgakopoulos President and Chief Scientific Officer, said today that "We are very excited about the progress for our first product, the NeoEpCAM Detection Kit(TM) and this financing will help to complete our validation studies and carry us closer to commercialization." Dr. Georgakopoulos went on to say, "We have made a quantum leap in the field of nanotechnology with respect to in-vitro diagnostic (IVD) testing and are extremely excited about our future projects."

About Acrongenomics Inc.

Acrongenomics Inc. is a publicly trading biotechnology company that specializes in research, development, production, and distribution of solutions for Genomics, Proteomics and Diagnostics, currently focusing on the development of a platform comprised of molecular human diagnostic tools for various diseases.

For more information please visit www.acrongen.com.